Genetic Signatures Announces Strategic Channel Partnership with Almog Diagnostic for Market Entry into Israel
Sydney, 29th August 2023: Genetic Signatures, a leading innovator in molecular diagnostics, is pleased to announce a strategic channel partnership with Almog Diagnostic, facilitating our entry into the Israeli market. This exclusive partnership further enhances Genetic Signatures’ footprint in the Middle East, extending access to our patented 3base® technology and syndromic solutions for infectious diseases…
Read MoreGenetic Signatures Announces Strategic Partnership with Integrated Gulf Biosystems for Expanded Market Reach in the Middle East
Sydney, 22nd August, 2023: Genetic Signatures, a leading innovator in molecular diagnostics, is pleased to announce a new channel partner in the Middle East, Integrated Gulf Biosystems (IGB). With IGB’s headquarters in Dubai, the exclusive agreement allows Genetic Signatures to tap into the promising market of United Arab Emirates, Kingdom of Saudi Arabia, Bahrain and…
Read MoreWorld Antimicrobial Awareness Week 2022: Preventing Antimicrobial Resistance Together
Spread Awareness, Stop Resistance World Antimicrobial Awareness Week Antimicrobial resistance (AMR) Priority pathogens Integrated stewardship: Collaboration with clinical laboratories to optimise antimicrobial therapy Genetic Signatures 3-base™ EasyScreen™ Detection Kit for AMR testing Evaluation Studies World Antimicrobial Awareness Week The World Health Organisation (WHO) has declared antimicrobial resistance (AMR) as one the most challenging…
Read MoreOmicron BA.4 and BA.5 Subvariants
Contents Epidemiology Healthcare Burden and Public Health Response 3base™ Technology Confident Detection of All Known SARS-CoV-2 Variants with 3base™ Customer Experience with the EasyScreen™ SARS-CoV-2 Detection Kit (RP012) Contact your local team References Summary Omicron BA.4 and BA.5 subvariants now represent over half of all COVID-19 infections globally, due to new mutations enhancing viral transmission…
Read More3base Technology and Reliable Detection of SARS-CoV-2 Variants
Genetic Signatures announces the launch of their multiplex real-time SARS-CoV-2 Variant Detection Kit, which can specifically identify Omicron (B.1.1.529) and other key SARS-CoV-2 variants. Summary Genetic Signatures announces the development of their SARS-CoV-2 Variant Detection Kit, which can specifically identify the Omicron (B.1.1.529), Delta and Beta variants by detecting specific mutations, and includes a…
Read MoreThe EasyScreen™ SARS-CoV-2 Detection Kit has a 100% match by in silico analysis to the new Omicron variant of the SARS-CoV-2 virus and will efficiently detect the new variant.
A review of approximately one hundred Omicron genomic sequences available in global databases was undertaken and confirmed the EasyScreen™ SARS-CoV-2 Detection Kit has a 100% match by in silico analysis to the new Omicron variant of the SARS-CoV-2 virus. Technical Bulletin A SARS-CoV-2 variant of concern has recently been described in the media and scientific…
Read More